此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

参与梅尼埃病的遗传和生物体液因素及其与表型的相关性 (Menière09)

2026年11月12日 更新者:teggi roberto carlo、IRCCS San Raffaele

遗传学和生物体液因素在梅尼埃病中的作用

Aim of this work was to assess the role of polymorphisms belonging to genes involved in the regulation of ionic homeostasis in Caucasian patients with Ménière Disease (MD) and compare results with a cohort of patients affected by vestibular migraine and a cohort of non vestibular subjects

研究概览

详细说明

Ménière's Disease (MD) is an inner ear disorder characterized by episodic vertigo, fluctuating sensorineural hearing loss and aural fullness ; endolymphatic hydrops is commonly associated with the pathophysiology of the disorder, although current data support the hypothesis that hydrops is an epiphenomenon associated with different inner ear disorders. The frequency of familial cases has been estimated in the range between 5 and 15% and it has been hypothesized that the disorder may arise from the interplay of genetic and environmental factors. Different candidate genes have been studied, although to date genetic investigation produced no conclusive results .

Among others, considering the importance of ionic homeostasis in the inner ear for the maintenance of endocochlear potential, genetic of fluid and ionic homeostasis have been included. A mutation of KCNQ1 and KCNE1 channels, co-expressed in the inner ear and in the heart, leads to a severe sensorineural deafness and a collapse of the cochlear scala media as seen in Jervell and Lange-Nielsen syndrome.

The aim of this work was to assess the role of genetic polymorphisms located in genes involved in the regulation of ionic transport on an Italian population of patients with definite MD.

研究类型

观察性的

注册 (估计的)

250

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Italy
      • Milan、Italy、意大利、20132
        • 招聘中
        • IRCCS San Raffaele
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

概率样本

研究人群

Patients were included if they fulfilled criteria for definite unilateral MD according to the Barany Society; in subjects enrolled before 2015 a retrospective analysis of data confirmed Barany criteria

描述

Inclusion Criteria:

  • Patients with definite Menière's Disease according to the criteria of the Barany Society

Exclusion Criteria:

  • surgically treated before the examination or if they had undergone intratympanic therapy with steroids or gentamicin

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_CONTROL
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
Menière's Disease; vestibular migraine

Enrolled subjects should fulfil criteria for definite Menière's Disease (group MD) or definite Vestibular Migraine (VM) according to the ongoing criteria of the Barany Society. Moreover a cohort of non vertiginous subjects will be enrolled. A signed informed consent will be obtained by all subjects. A withdrawal for blood sample will be obtained to study genetic and biohumoral factors in the 3 groups

A blood withdrawal will be obtained to assess

其他名称:
  • 表型收集

Genetics of ionic transporters and biohumoral factors related to Meniere's Disease and differences with vestibular migraine subjects

Menière's Disease (MD)

To be included, subjects should fulfill definite diagnostic criteria for MD. A blood withdrawal will be obtained to assess genetic and biohumoral aspects

A blood withdrawal will be obtained to assess

其他名称:
  • 表型收集

Genetics of ionic transporters and biohumoral factors related to Meniere's Disease and differences with vestibular migraine subjects

Vestibular Migraine (VM)

To be included, subjects should fulfill definite diagnostic criteria for VM. A blood withdrawal will be obtained to assess genetic and biohumoral aspects

A blood withdrawal will be obtained to assess

其他名称:
  • 表型收集

Genetics of ionic transporters and biohumoral factors related to Meniere's Disease and differences with vestibular migraine subjects

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Genetic of ionic transporters
大体时间:From enrollment to the end of enrollment in december 2027

Genomic DNA of all cases and controls was extracted from venous blood by standard methods. 36 Single Nucleotide Polymorphisms (SNPs) were genotyped using TaqMan® OpenArray™ Genotyping System (Life Technologies, Foster City, CA). All DNA samples were loaded and amplified according to the manufacturer's instructions.

From enrollment to the end of enrollment in december 2027

次要结果测量

结果测量
措施说明
大体时间
Biohumoral factors specifically Interleukins, Endogenous Ouabain
大体时间:From enrollment to the end of the study in july 2027

Values of interleukins and endogenous ouabain is evaluated in blood sample of patients and compared with values in blood samples of a control group and in patients with vestibular migraine

From enrollment to the end of the study in july 2027

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年4月9日

初级完成 (估计的)

2027年4月9日

研究完成 (估计的)

2027年4月12日

研究注册日期

首次提交

2026年4月1日

首先提交符合 QC 标准的

2026年4月1日

首次发布 (实际的)

2026年4月8日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

A dataset with genetic data will be shared as a excel file

IPD 共享时间框架

Initial data will be available in december

IPD 共享访问标准

Reviewers for the journal in which the work is submitted. On request, other researchers may access to data

IPD 共享支持信息类型

  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅